From: Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis
Risk factor | Descriptive analysis | Â | Â | Univariable analysis | |
---|---|---|---|---|---|
Calcinosis | Â | OR [95% CI] | p-value | ||
Yes | No | ||||
Gender | n (%) | 0.0138 | Â | Â | |
 Male | 33 (39.3) | 144 (26.3) |  | 1.811 [1.123–2.919] | 0.0148 |
 Female | 51 (60.7) | 403 (73.7) |  |  |  |
Age (years) | median (IQR) | Â | Â | Â | |
 At symptom onset | 6 (4.2–9) | 5.5 (3.6–9.3) |  |  |  |
 At diagnosis | 8 (5.4–10.6) | 6.3 (4.2–9.8) | 0.0424 |  |  |
 Time to diagnosis (months) | 8.8 (2–23.6) | 3.8 (1.9–8.9) | 0.0011 | 1.029 [1.016–1.043] | < 0.0001 |
Ethnicity | n (%) | Â | Â | Â | |
 Hispanic | 12 (14.3) | 83 (15.2) |  |  |  |
Race | Â | Â | 0.0047 | Â | Â |
 Caucasian | 61 (72.6) | 458 (83.7) |  |  |  |
 African-American | 19 (22.6) | 63 (11.5) |  | 2.264 [1.270–4.038] | 0.0056 |
 Missing | 4 (4.8) | 26 (4.8) |  |  |  |
JDM Category | n (%) | Â | Â | Â | |
 Amyopathic | 2 (2.4) | 7 (1.3) |  |  |  |
 Probable | 61 (72.6) | 429 (78.4) |  |  |  |
 Definite | 8 (9.5) | 40 (7.3) |  |  |  |
 Missing | 13 (15.5) | 71 (13) |  |  |  |
Clinical features | n (%) | Â | Â | Â | |
 Lipodystrophy | 11 (13.1) | 13 (2.4) | < 0.0001 | 5.993 [2.588–13.874] | < 0.0001 |
 Joint contractures | 23 (27.4) | 35 (6.4) | < 0.0001 | 5.343 [2.964–9.635] | < 0.0001 |
 Cutaneous ulceration | 12 (13.5) | 23 (4.2) | 0.001 | 3.748 [1.787–7.862] | 0.0005 |
 Gottron’s or Heliotrope | 50 (59.5) | 244 (44.6) | 0.0176 | 1.754 [1.099–2.800] | 0.0186 |
 Dysphagia or dysphonia | 26 (31) | 107 (19.6) | 0.0178 |  |  |
 Small joint arthritis | 25 (29.8) | 115 (21.0) | 0.041 |  |  |
 Malar or facial erythema | 31 (36.9) | 182 (33.3) |  |  |  |
 V or Shawl sign | 9 (10.7) | 25 (4.6) | 0.0377 | 2.410 [1.083–5.361] | 0.0311 |
 Periungal Telangiectasia | 40 (47.6) | 225 (41.1) |  |  |  |
 Cardiac involvement | 4 (4.8) | 10 (1.8) |  |  |  |
 Gastrointestinal ulceration | 3 (3.6) | 7 (1.3) |  |  |  |
 Interstitial lung disease | 4 (4.8) | 11 (2.0) |  |  |  |
 Any organ involvementa | 9 (10.7) | 25 (4.6) | 0.0333 | 2.506 [1.127–5.573] | 0.0243 |
 Large joint arthritis | 26 (31) | 147 (26.9) |  |  |  |
 Muscle enzyme elevation | 74 (88.1) | 481 (87.9) |  |  |  |
 Severe muscle weakness | 2 (2.4) | 14 (2.6) |  |  |  |